Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > 01093 CSPC PHARMA > Company Profile
01093 CSPC PHARMA
7.000
-0.110-1.55%
Symbol
01093
Company Name
CSPC PHARMA
ISIN
HK1093012172
Listing Date
06/21/1994
Establishment Date
06/16/1992
Registration
Hong Kong, China
Chairman
Dongchen Cai
Secretary
Taian Luo
Audit Institution
Deloitte-Guan Huang Chen Fang accountants
Company Category
Overseas registration of Mainland State-owned Assets control
Registered Office
Room 3206, 32 / F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong, China
Head Office and Principal Place of Business
Room 3206, 32 / F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong
Fiscal Year Ends
12-31
Employees
25147
Market
Hong Kong motherboard
Phone
(852) 2802 3011
Fax
(852) 2802 4552
Email
info@cspc.hk
Business
Stone Pharmaceutical Group Co., Ltd. is an investment holding company mainly engaged in drug production and sales. The company sells its products under the brand name "Stone Medicine". The company includes four business divisions: proprietary medicine, antibiotics (intermediates and API), vitamin C (API) and caffeine and other (API), respectively engaged in the production and sales of related drugs. The company's proprietary medicines include antibiotics, cardio-cerebrovascular drugs, diabetes drugs, psychiatric drugs, antineoplastic drugs and traditional Chinese medicine products. Through its subsidiaries, the company is also engaged in providing drug research and development services and sewage and drug by-product treatment business.
Profile
Stone Pharmaceutical Group Limited ("Stone Pharmaceutical Group") is a leader in China's pharmaceutical industry. The company was listed on the main board of the Stock Exchange of Hong Kong in 1994 and is one of the well-known pharmaceutical listed companies in Hong Kong. it is now one of the Hang Seng Composite Index, Hang Seng Hong Kong Chinese Enterprises Index and Hang Seng mainland China 100 stocks. Stone Pharmaceutical Group has three business sectors: innovative drugs, general pharmaceuticals and API drugs, which are mainly engaged in the development, production and sales of medicines and related products. Proprietary medicine products mainly include antibiotics, cardio-cerebrovascular drugs, antipyretic and analgesic drugs, digestive system drugs, antineoplastic drugs and proprietary Chinese medicines, and so on. Among them, "Enbipu", "Oleining", "Xuanning", "Duomesu", "Jin Youli" and "Nuolining" are the best-selling innovative drug products in China. API products mainly include antibiotics, vitamin C and caffeine series. Shiyao Group's main production base is located in Shijiazhuang City, Hebei Province, China. Evaluated by the World Brand Laboratory, one of the top five brand value evaluation institutions in the world, the "Stone Medicine" brand has been selected as the "500 most valuable Brand in China" for 11 times since 2004. In terms of fulfilling its social responsibility, Shiyao Group always takes the lead in supporting social welfare undertakings enthusiastically, and is always indispensable in activities such as SARS, Indonesian tsunami, Wenchuan earthquake, Yushu earthquake, medical treatment of seriously ill children, voluntary services, and so on. With real things, Stone Pharmaceutical Group continues to give back to the community.
Company Overview
Stone Pharmaceutical Group Co., Ltd. is an investment holding company mainly engaged in drug production and sales. The company sells its products under the brand name "Stone Medicine". The company includes four business divisions: proprietary medicine, antibiotics (intermediates and API), vitamin C (API) and caffeine and other (API), respectively engaged in the production and sales of related drugs. The company's proprietary medicines include antibiotics, cardio-cerebrovascular drugs, diabetes drugs, psychiatric drugs, antineoplastic drugs and traditional Chinese medicine products. Through its subsidiaries, the company is also engaged in providing drug research and development services and sewage and drug by-product treatment business.
CEO: Dongchen Cai
Market: Hong Kong motherboard
Futu Hot List
HKUSCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top